EGFR and non-small cell lung carcinoma: In head-to-head clinical trials, afatinib, dacomitinib and osimertinib have all demonstrated superiority to first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) (1–3).